Abstract: A method for the treatment of neurological disorders, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or of formula II (formulae set out on pages following the Examples), whereinR.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from:hydrogen,(1-3C)perfluoroalkyl,halo, nitro and cyano;R.sup.5 is a (1-5C)alkyl group;or a pharmaceutically acceptable salt thereof.Also provided are compounds and pharmaceutical compositions suitable for the treatment of neurological disorders.

Abstract: A carbapenem compound of the formula (I) ##STR1## wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;R.sup.2 is hydrogen or C.sub.1-4 alkyl;R.sup.3 is hydrogen or C.sub.1-4 alkyl;R.sup.4 is hydroxy or carboxy;and the phenyl ring is optionally further substituted by one or two substituents selected from halo, cyano, C.sub.1-4 alkyl, nitro, hydroxy, carboxy, C.sub.1-4 alkoxy, trifluoromethyl, C.sub.1-4 alkoxycarbonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylcarbamoyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino sulphonic acid, C.sub.1-4 alkylS(O).sub.n --(wherein n is 0-2), N-C.sub.1-4 alkanesulphonamido, C.sub.1-4 alkanoylamino and C.sub.1-4 alkanoyl(N-C.sub.1-4 alkyl)amino:provided that the phenyl ring is substituted by at least one carboxy; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

Abstract: Biocidal proteins isolated from seeds have been characterised, in particular proteins isolated from members of the Brassicaceae, Compositae and Leguminosae families including Raphanus, Brassica, Sinapis, Arabidopsis, Dahlia, Cnicus, Lathyrus and Clitoria. The proteins show a wide range of antifungal activity and some are active against Gram-positive bacteria. All share a common amino acid sequence. DNA encoding the proteins has been isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.

Abstract: The present invention provides a compound of the formula (I) ##STR1## wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;R.sup.2 is hydrogen or C.sub.1-4 alkyl;Z is carboxy, sufonic acid, tetrazol-5-yl or C .sub.1-4 alkylsulfonylcarbamoyl (--CONHSO.sub.2 C.sub.1-4 alkyl);A is a phenyl or thienyl ring;and A is optionally further substituted by one or two substituents or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.

Abstract: A surfactant comprising a carboxylic acid ester or amide carrying a terminal strong acid group selected from carboxymethyl, sulphate, sulphonate, phosphate and phosphonate, suitable for stabilising dispersions of solids in organic liquids and oil/water emulsions, processes for the preparation of the surfactant and dispersions and emulsions containing the surfactant. A preferred species of the surfactant is a poly(hydroxyalkanecarboxylic acid) having the strong acid group attached, either directly or through a linking group, to a terminal hydroxy or carboxylic acid group.

Abstract: This invention relates to a maize plant and a method of producing the same, which is tolerant to high pH soil. More particularly, this invention relates to the introgression in maize of identified genetic material capable of causing the plant to be tolerant to high pH soil. Additionally, the present invention relates to the introgression, with precision and accuracy, of such desired genetic material from one or more parent plants into progeny plants. The present invention also covers the maize plants containing the high pH tolerance material.

Abstract: Compounds of formula I ##STR1## wherein J, B, L, X, m and M have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: A supported or cast film of a polyhydroxyalkanoate polymer, such as a polyhydroxybutyrate/valerate polymer, can be prepared by applying a layer of molten polymer to a cool (typically 4.degree. to 20.degree. C.) surface not substantially above the glass transition temperature of the polymer, so as to form a solid, glassy film with a high density of nucleation sites; subsequently the temperature of the film so formed is raised, for example to 40.degree. C. or more, towards the optimum temperature for growth of the polymer's spherulites effectively separating the film formation/nucleation step from the crystallisation step (growth of spherulites around the nucleation sites). Smaller crystallites are formed, and the film has improved barrier properties.

Abstract: A herbicidal composition comprising (i) N-phosphonomethylglycine or an agriculturally acceptable salt thereof in combination with (ii) paraquat or diquat or a mixture thereof and (iii) a herbicide which functions as a photosystem II inhibitor, for example diuron, chlortoluron, isoproturon, linuron, tebuthiuron, bentazone, oxadiazon, bromacil, ametryne, atrazine, cyanazine, hexazinone, metribuzin, simazine or terbuthylazine.

Abstract: The present invention relates to certain novel amide derivatives which are pyrido[3,4-d]pyrimidin-7-ylacetamides which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these amide derivatives, processes for preparing the amide derivatives, pharmaceutical compositions containing such amide derivatives and methods for their use.

Abstract: The invention discloses a process for the preparation of a halogenated alcohol of formula:CF.sub.3 --CXCl--CH(OH)--CH.dbd.C(CH.sub.3).sub.2wherein X is bromo or chloro which comprises reacting a compound of formula:CF.sub.3 CHXClwith 3-methylbut-2-en-1-al in the presence of a strong base and an inert solvent. The products are useful intermediates for the manufacture of insecticides.

Abstract: This invention embodies compositions comprising herbicidally effective compounds corresponding to the formula ##STR1## in which R.sub.1 and R.sub.2 are independently methyl or ethyl,X is H, methyl, chlorine, bromine, fluorine;Y is chlorine, bromine, fluorine; andn is 0, 1 or 2and a non-phytotoxic antidotally effective amount of an antidote therefor selected from the group of amides of haloalkanoic acids, including oxazolidines and thiazolidines, aromatic oxime derivatives, thiazole carboxylic acids and derivatives, substituted phenylpyrimidines, 2-(dichloroacetyl)-2-methyl-1,3-dioxolane and 2-(dichloromethyl)-2-thiazoline.

Abstract: The present invention relates to carbapenems and provides a compound of the formula (I) ##STR1## wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;R.sup.2 is hydrogen or C.sub.1-4 alkyl;R.sup.3 is hydrogen or C.sub.1-4 alkyl;A is a 5-membered heteroaryl ring containing one nitrogen atom and up to two additional heteroatoms selected from nitrogen, oxygen and sulphur; and is bonded to the nitrogen of the linking carbamoyl group by a carbon atom in the ring, is substituted with the carboxy group on a carbon atom in the ring and is optionally further substituted on a carbon atom in the ring; andin any ring --NH--, H is optionally replaced by C.sub.1-4 alkyl; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them are also described.

Abstract: A process for the manufacture of N-phosphonomethyliminodiacetic acid which comprises: 1) reacting iminodiacetic acid with phosphorous acid and a source of formaldehyde in aqueous solution in the presence of concentrated sulphuric acid; 2) filtering and recovering the N-phosphonomethyliminodiacetic acid product precipitated in stage (1); 3) recovering the filtrates from stage (2) and optionally removing a proportion of the water therefrom; 4) transferring the filtrates from stage (3) to a further reaction stage in which further iminodiacetic acid is reacted with phosphorous acid and a source of formaldehyde in the presence of sulphuric acid; and thereafter 5) repeating stages (1), (2), (3) and (4) in a plurality of re-cycles.

Abstract: The present invention provides a compound of the formula: ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein:A is a group of the formula (IA) or (IB): ##STR2## R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl;R.sup.3 and R.sup.4 are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O).sub.x (wherein x is zero, one or two), --CONR.sup.5 -- or --NR.sup.5 -- or wherein R.sup.5 is hydrogen or C.sub.1-4 alkyl;or X is alkenediyl containing 1-6 carbon atoms optionally interrupted by O, S(O).sub.x or --NR.sup.5 --.

Abstract: This invention embodies compositions comprising herbicidally effective compounds corresponding to the formula ##STR1## in which R.sub.1 and R.sub.2 are independently methyl or ethyl,X is H methyl, chlorine, bromine, fluorine;Y is chlorine, bromine, fluorine: andn is 0, 1, or 2 and a non-phytotoxic antidotally effective amount of an antidote therefore selected from the group of amides of haloalkanoic acids, including oxazolidines and thiazolidines, aromatic oxime derivatives, thiazole carboxylic acids and derivatives, substituted phenylpyrimidines, 2-(dichloroacetyl)-2-methyl-1,3-dioxolane and 2-(dichloromethyl)-2-thiazoline.

Abstract: A process for the separation of at least one isomer from a mixture of isomers of a tetrahydropyran-2-one, having at least two chiral centers which comprises selective reaction of at least one isomer with a reagent catalyzed by a hydrolase enzyme whereby at least one isomer is preferentially converted into a distinct chemical species from the other isomers so that it is susceptible of separation by an appropriate chemical or physical separation process in which the tetrahydropyran-2-one is of Formula (1): ##STR1## wherein: Z is --H or a protecting group susceptible of reaction with the reagent under the influence of the enzyme; andY is formyl or protected formyl.

Abstract: Melt processed articles of improved color and odor can be produced from hydroxyalkanoic acid polymers if they are melt processed in the presence of a temperature stable sulphite salt, and compositions for use in such processes are disclosed.

Abstract: The present invention relates to a method for the amplification of a target nucleotide sequence using a first primer comprising 1) a target binding nucleotide moiety which is substantially complementary to the desired portion of the target nucleotide sequence; and 2) a polynucleotide tail. The first primer is such that while an extension product thereof may itself serve as a template for primer extension to form an amplification primer extension product, formation of an amplification primer extension product comprising a sequence complementary to the polynucleotide tail is inhibited.

Abstract: The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.